logo-loader
viewQ BioMed Inc.

Full interview: Q BioMed boss says 'all systems go' to prep for commercializing cancer bone pain drug

Q BioMed Inc (OTCMKTS:QBIO) CEO Denis Corin tells Proactive since announcing that the FDA has cleared its contract manufacturer IsoTherapeutics Group LLC to produce the company’s non-opioid cancer bone pain drug Strontium-89 Chloride USP, its been 'all systems go' to prep towards commercialization.

Corin says he is excited to potentially have the drug on the market by the end of January or early February next year.

Quick facts: Q BioMed Inc.

Price: 1.695 USD

OTCQB:QBIO
Market: OTCQB
Market Cap: $38.6 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Q BioMed Inc. named herein, including the promotion by the Company of Q BioMed Inc. in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Q BioMed advancing its liver cancer treatment through the pipeline

Q BioMed Inc (OTCMKTS:QBIO) CEO Denis Corin tells Proactive the biotech will advance Uttroside-B in its portfolio and move it quickly towards monetization. Corin says the efficacy of Uttroside-B, a potent saponin, was demonstrated in a preclinical study published in the November 2016 issue of...

2 weeks, 1 day ago

2 min read